Skip Navigation

Link to  the National Institutes of Health NIDA NEWS NIDA News RSS Feed
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Keep Your Body Healthy
Go to the Home pageGo to the About Nida pageGo to the News pageGo to the Meetings & Events pageGo to the Funding pageGo to the Publications page
PhysiciansResearchersParents/TeachersStudents/Young AdultsEn Español Drugs of Abuse & Related Topics
NIDA News Release Contact: Michelle Muth
301-443-6245
FOR RELEASE, May 27, 2001

Study Sheds Light on Role of Gender Differences in the Risk of HIV Infection Among Injection Drug Users
High-risk sexual activity plays key role


HIV risk factors among injection drug users (IDUs) differ markedly by gender, according to a 10-year study funded by the National Institute on Drug Abuse (NIDA). A recent study by researchers at the Johns Hopkins University reported that while drug-related risk behaviors and homosexual activity are the most important predictors of HIV seroconversion among males, factors consistent with high-risk heterosexual activities are the main predictors among females. The findings, reported in the May 28 issue of the Archives of Internal Medicine, provide insight into the relationship between gender and high-risk sexual behaviors in the development of HIV infection.

"Early studies of injection drug users suggested that most HIV infections were due primarily to sharing needles," said NIDA Director Alan I. Leshner, Ph.D. "This study adds to the body of evidence that supports the need for gender-specific interventions in the treatment of that group of drug users."

Between 1988 and 1998, a team of researchers, led by Dr. Steffanie Strathdee at the Johns Hopkins University Bloomberg School of Public Health, examined both drug related and sexual risk factors for HIV transmission in a study of more than 1,800 injecting drug users in Baltimore, Maryland. Study participants were aged 18 or older, did not have an AIDS defining illness at enrollment, and reported a history of illicit injection drug use within the previous 10 years. Through semi-annual interviews, researchers collected data on drug use history, sociodemographics, and drug use and sexual behavior within the last 6 months. Blood samples were also obtained at each study visit. Researchers used commercial HIV and antibody ELISA to identify those participants who had become HIV positive since their last visit.

Dr. Strathdee and her colleagues found that the greatest predictor for HIV seroconversion among both male and female IDUs was high-risk sexual behavior. Study findings revealed that male injection drug users who reported recent homosexual activity were four times more likely to become infected with HIV.

Among females, indicators of high-risk heterosexual activity outweighed needle-sharing behaviors as independent predictors of HIV seroconversion. HIV incidence was more than two times higher among women who reported recently having sex with another injection drug user.

Another common predictor of HIV seroconversion observed by researchers among both male and female IDUs was younger age. Investigators found that IDUs who were aged 30 or younger at enrollment were more than twice as likely to seroconvert than those aged 40 or older.

"This is consistent with several reports which indicate that younger IDUs are more likely to engage in needle sharing and other behaviors that place them at higher risk of acquiring HIV and hepatitis B or C viruses," stated Dr. Strathdee.

Note to reporters: The full text of this article will be available on the Archives of Internal Medicine's Web site at http://www.ama-assn.org/


The National Institute on Drug Abuse is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports more than 85 percent of the world's research on the health aspects of drug abuse and addiction. The Institute carries out a large variety of programs to ensure the rapid dissemination of research information and its implementation in policy and practice. Fact sheets on the health effects of drugs of abuse and other topics can be ordered free of charge in English and Spanish by calling NIDA Infofax at 1-888-NIH-NIDA (644-6432) or 1-888-TTY-NIDA (889-6432) for the deaf. These fact sheets and further information on NIDA research and other activities can be found on the NIDA home page at http://www.drugabuse.gov.

[News Release Index]



NIDA Home | Site Map | Search | FAQs | Accessibility | Privacy | FOIA (NIH) | Employment | Print Version



National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. Last updated on Thursday, September 4, 2008. The U.S. government's official web portal